38 unknown, 27 completed, 17 recruiting, 8 terminated. 61 Phase 2, 28 Phase 3, 9 Phase 1, 3 Not applicable, 2 Phase 4.
Follow Tegafur: new trials by email Literature Review of Tegafur trials Research Report on Tegafur
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Exploring the Efficacy of Ferrous Sulfate/Ferrous Succinate Combined With Serplulimab and SOX Regimen in Neoadjuvant Therapy for Gastric Cancer: A Prospective Cohort Study Ferrous succinate, Ferrous Sulfate, Serplulimab - Gastric Neoplasms | Phase 2 | Not yet recruiting | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 54 | 2026-09-01 | 2026-10-14 |
| Neoadjuvant and Adjuvant Therapy Studies of Sintilimab Combined With Chemotherapy With or Without Ipilimumab N01 in Resectable Gastric/Gastroesophageal Junction Adenocarcinoma tegafur, Gimeracil and Oteracil Potassium Capsules, Sintilimab Placebo, Sintilimab - Resectable Gastric/Gastroesophageal Junction Adenocarcinoma | Phase 2 / Phase 3 | Recruiting | Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. | 720 | 2026-07-31 | 2026-08-14 |
| Perioperative HLX10 (Serplulimab) With S-1+Oxaliplatin (SOX) in Locally Advanced and PD-L1-Positive Gastric or Esophagogastric Junction Adenocarcinoma serplulimab, Placebo - Gastric Adenocarcinoma, Gastroesophageal Junction (GEJ) Adenocarcinoma | Phase 2 | Recruiting | National Cancer Center, Japan | 136 | 2026-07-15 | 2026-08-05 |
| A Clinical Study Comparing Anti-HER2 Therapy Combined With Chemotherapy to Chemotherapy Alone as Adjuvant Therapy Following Surgery for Stage IB-II Gastric Cancer With High HER2 Expression. Trastuzumab, Monotherapy with tegafur for stage IB gastric cancer, Stage II gastric cancer treated with the SOX or XELOX regimens - IB-II Gastric Cancer | Phase 2 | Recruiting | Xijing Hospital | 120 | 2026-07-01 | 2026-08-26 |
| Phase III Study to Compare GFH375 and Chemotherapy in Patients With KRAS G12D-Mutant Metastatic Pancreatic Cancer GFH375, Chemotherapy - Metastatic Pancreatic Cancer | Phase 3 | Recruiting | Genfleet Therapeutics (Shanghai) Inc. | 320 | 2025-12-04 | 2026-08-14 |
| Conversion Therapy Plus Surgery and Radiotherapy for Retroperitoneal Nodal Metastases in Gastric Cancer SOX regimen, CAPEOX regimen, PD-1 inhibitor - Gastric Adenocarcinoma, Stomach Neoplasms | Phase 2 | Recruiting | Jinbo Yue | 54 | 2025-10-01 | 2026-10-15 |
| Perioperative Therapy for HER2-negative Hepatoid Adenocarcinoma of Stomach Perioperative treatment with albumin-bound paclitaxel, oxaliplatin, tegafur,gimeracil and oteracil porassium capsules and sintilimab. - Hepatoid Adenocarcinoma of Stomach | Phase 2 | Recruiting | Peking University Cancer Hospital & Institute | 30 | 2025-09-18 | 2025-12-02 |
| Neoadjuvant Radiotherapy Plus Tegafur, Oxaliplatin and Iparomlimab and Tuvonralimab in Resectable Gastric and GE-junction Cancer : A Randomized, Two-arm, Prospective Trial (TRIUNITE-05) Iparomlimab and Tuvonralimab, Oxaliplatin, Tegafur - Immunotherapy, Gastric Cancer (GC) | Phase 2 | Recruiting | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | 40 | 2025-07-23 | 2025-09-10 |
| The Efficacy and Safety of Benmelstobart for GC/EGC surgery, Benmelstobart, tegafur - Gastric Cancer | Not applicable | Not yet recruiting | Xijing Hospital | 48 | 2024-10-16 | 2024-09-19 |
| The Efficacy and Safety of Tislelizumab Combined With Anlotinib and S1 Plus Oxaliplatin as Neoadjuvant Therapy for the Locally Advanced Adenocarcinoma of Esophagogastric Junction Tislelizumab, Anlotinib, Oxaliplatin - Immunotherapy Gastroesophageal Junction | Phase 2 | Unknown | Fujian Cancer Hospital | 28 | 2024-08-01 | 2024-05-07 |
| Adjuvant Treatment With Serplulimab，Trastuzumab and SOX in the HER-2 Positive GC/GEJC Serplulimab, Trastuzumab, Oxaliplatin + Tegafur - HER2-positive Gastric Cancer | Phase 2 | Not yet recruiting | The First Affiliated Hospital of Zhengzhou University | 42 | 2024-07-15 | 2024-06-03 |
| Effect and Safety of Huaier Granule Versus SOX Regimen in Gastric Cancer Patients Huaier granule, Oxaliplatin, Tegafur, Gimeracil and Oteracil Potassium - Gastric Cancer | Phase 4 | Not yet recruiting | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 702 | 2024-07-01 | 2024-06-24 |
| Efficacy and Safety of Anti-PD-1, Thymalfasin, and SOX in Neoadjuvant Treatment of cStage III Gastric/Gastroesophageal Junction Adenocarcinoma Serplulimab, thymalfasin, Oxaliplatin - Gastric Cancer, Esophagogastric Junction Adenocarcinoma | Phase 2 | Recruiting | Zekuan Xu | 30 | 2024-06-14 | 2026-03-03 |
| PPIO-008 Tislelizumab Combined With S-1 in Patients With ypT+N0 ESCC After Radical Resection With Neoadjuvant STUDY Tegafur - Esophageal Squamous Cell Carcinoma | Phase 2 | Recruiting | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | 45 | 2024-05-07 | 2024-07-17 |
| HR070803 in Combination With Oxaliplatin, S-1 Versus NALIRIFOX as Adjuvant Therapy for Pancreatic Cancer HR070803, Oxaliplatin, Tegafur - Efficacy and Safety | Phase 2 | Not yet recruiting | The First Affiliated Hospital with Nanjing Medical University | 120 | 2024-04-20 | 2024-04-25 |
| AK104 in Combination With AK112 Plus Chemotherapy(SOX/XELOX) as First-line Treatment for Advanced G/GEJ Cancer Cadonilimab, Ivonescimab, XELOX - Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma | Phase 2 | Recruiting | Harbin Medical University | 50 | 2024-04-10 | 2024-06-27 |
| Irinotecan Liposome Combined With Oxaliplatin and Tegafur as Adjuvant Therapy for Pancreatic Cancer Irinotecan liposome injection - Pancreatic Cancer, Adjuvant Therapy | Not applicable | Recruiting | Kuirong Jiang | 53 | 2024-04-08 | 2024-04-11 |
| Nimotuzumab Plus Definite Chemoradiotherapy(dCRT) in Elderly Patients With Esophageal Squamous Cell Carcinoma Nimotuzumab, Tegafur, radiotherapy - Esophageal Squamous Cell Carcinoma | Phase 2 | Recruiting | The First Affiliated Hospital with Nanjing Medical University | 95 | 2024-03-31 | 2025-05-25 |
| Combination Immunotherapy of Adebrelimab With Apatinib and Tegafur, Gimeracil and Oteracil Potassium Capsules for Immune Rechallenge Therapy in Esophageal Squamous Cell Carcinoma Adebrelimab, Apatinib, Tegafur - Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma | Phase 2 | Recruiting | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 32 | 2024-03-11 | 2026-06-04 |
| Consolidation of Toripalimab After Chemoradiotherapy in Elderly Esophageal Cancer (EC-CRT-007) S-1, Toripalimab, Intensity-modulated radiotherapy - Locally Advanced Esophageal Squamous Cell Carcinoma | Phase 2 | Recruiting | Sun Yat-sen University | 140 | 2024-03-01 | 2024-03-12 |
Showing 20 of 101. Sign in to see all of them.
Stomach Neoplasms (25) · Colorectal Neoplasms (12) · Colonic Neoplasms (9) · Carcinoma, Hepatocellular (6) · Rectal Neoplasms (6) · Pancreatic Neoplasms (5) · Biliary Tract Neoplasms (4) · Breast Neoplasms (4) · Carcinoma, Non-Small-Cell Lung (4) · Esophageal Squamous Cell Carcinoma (4) · Esophageal Neoplasms (3) · Gallbladder Neoplasms (3) · Head and Neck Neoplasms (3) · Squamous Cell Carcinoma of Head and Neck (3) · Adenocarcinoma (2)
Fudan University (5) · Taiho Pharmaceutical Co., Ltd. (4) · Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan (4) · National Health Research Institutes, Taiwan (3) · National Taiwan University Hospital (3) · Sun Yat-sen University (3) · The First Affiliated Hospital with Nanjing Medical University (3) · Beijing YouAn Hospital (2) · Chang Gung Memorial Hospital (2) · Chinese Academy of Medical Sciences (2) · Daping Hospital and the Research Institute of Surgery of the Third Military Medical University (2) · Fujian Cancer Hospital (2) · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (2) · University of Pittsburgh (2) · Xijing Hospital (2)
China (44) · Japan (18) · Taiwan (15) · United States (7) · South Korea (6) · United Kingdom (3) · Australia (2) · Brazil (2) · Denmark (2) · France (2) · Italy (2) · Norway (2) · Spain (2) · Turkey (Türkiye) (2) · Belgium (1)
Kenichi Sugihara, MD, PhD (3) · Chandra P. Belani, MD (2) · Yihebali Chi, doctor (2) · Aiping Zhou (1) · Aiping Zhou, Doctor (1) · Ashraf Abdelaziz, MD/PhD (1) · Been Ren Lin, Ph.D (1) · Bin Wang (1) · Bruce D. Minsky, MD (1) · Caigang Liu, doctor (1) · Chia-Jui Yen Yen, MD. PhD (1) · Chih-Hung Hsu, M.D. Ph.D. (1) · Chih-Hung Hsu, M.D.Ph.D (1) · Ching-Yun Hsieh, MD (1)
PMID 36188432, PMID 10442378, PMID 11098486, PMID 16648506, PMID 16675478, PMID 16945170, PMID 17264338, PMID 17414457, PMID 17948223, PMID 18048821, PMID 19204202, PMID 19331206, PMID 19638976, PMID 21183517, PMID 21338641, PMID 22769569, PMID 24942277, PMID 25671770, PMID 26439700, PMID 26884585, PMID 27913881, PMID 28441966, PMID 29372461, PMID 29677641, PMID 30425843, PMID 31180819, PMID 32583567, PMID 33435909, PMID 34133211, PMID 34351356, PMID 35419831, PMID 35798468, PMID 36990609, PMID 37016303, PMID 37195667, PMID 37501640, PMID 38902994, PMID 38996201, PMID 40022044, PMID 41749205
2023 (1), P30CA022453 (1), U10CA012027 (1)